Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
| Autor: | Angela Maria Seco Segura, Fernando García-Seco, Jesús Moreno-Fernández, José Alberto García-Seco, Pedro Jesus Rozas Moreno, Miguel Aguirre Sánchez-Covisa |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Time Factors Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Glucagon-Like Peptide-1 Receptor 03 medical and health sciences Lixisenatide chemistry.chemical_compound 0302 clinical medicine Internal medicine Diabetes mellitus Weight Loss Internal Medicine medicine Humans Hypoglycemic Agents 030212 general & internal medicine Obesity Prospective Studies Glycemic Aged Glycated Hemoglobin Nutrition and Dietetics Liraglutide business.industry Therapeutic effect Type 2 Diabetes Mellitus Middle Aged medicine.disease Treatment Outcome chemistry Diabetes Mellitus Type 2 Spain Observational study Female Family Practice business Peptides Biomarkers medicine.drug |
| Zdroj: | Primary care diabetes. 14(1) |
| ISSN: | 1878-0210 |
| Popis: | Aim Liraglutide and lixisenatide improved glycemic control, weight and cardiovascular risk factors (CVRF) in type 2 diabetes mellitus (T2DM) patients. Our objective was to analyze clinical efficacy and safety differences in routine clinical practice. Methods A 24-week prospective observational study to compare the effect of liraglutide versus lixisenatide in obese T2DM patients in routine clinical practice. The main objective was to analyze between-group glycosylated hemoglobin (HbA1c) differences at the end of the study. Secondary objectives included differences in body weight, other CVRF, changes in medication, side effects, satisfaction and safety. Results A total of 100 patients (50 liraglutide, 50 lixisenatide) were included. Both groups experienced a decrease in HbA1c values (liraglutide, −1.4%, CI 95% −2, −0.8, P Conclusions These results confirm the efficacy and safety of liraglutide and lixisenatide in routine clinical practice. Moreover, a different therapeutic effect between liraglutide and lixisenatide was detected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect